Arrowhead Pharmaceuticals (NASDAQ: ARWR) — Company Overview, News & Financial Data
Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics for intractable diseases, enhancing patient outcomes.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines treating intractable diseases by silencing the genes that cause them using RNA interference technology. The company utilizes its proprietary Targeted RNAi Molecule platform to deliver RNA interference therapeutics to specific cells and tissues, including the liver and lungs. Its drug development pipeline targets cardiometabolic conditions, cardiovascular diseases, severe hypertriglyceridemia, and pulmonary inflammatory disorders. Through internal clinical development and strategic pharmaceutical partnerships, the company advances targeted therapeutics designed to reduce the expression of disease-causing proteins.
Snapshot
Operations
Products and/or services of Arrowhead Pharmaceuticals
- RNA Interference Platform: Targeted drug delivery platform leveraging natural gene-silencing pathways to direct synthetic small interfering RNA molecules into specific cells and tissues, including liver hepatocytes and pulmonary epithelial cells, targeting disease-causing proteins.
- Cardiometabolic RNAi Therapeutics: Subcutaneous RNA interference candidate engineered to inhibit apolipoprotein C-III synthesis in liver tissue, evaluated in phase 3 clinical trials for adult patients with severe hypertriglyceridemia and familial chylomicronemia syndrome across global study sites.
- Cardiovascular RNAi Therapeutics: Subcutaneous RNA interference drug candidate designed to lower angiopoietin-like protein 3 production in liver tissue, evaluated in phase 3 clinical studies to reduce low-density lipoprotein cholesterol in homozygous familial hypercholesterolemia patients.
- Pulmonary Disease Therapeutics: Inhaled RNA interference therapeutic designed to inhibit the expression of the receptor for advanced glycation end products in lung tissue, evaluated in clinical trials for patients with muco-obstructive and inflammatory pulmonary diseases.
- Pharmaceutical Manufacturing Facilities: In-house active pharmaceutical ingredient synthesis and drug product manufacturing facilities located in Verona and Madison, Wisconsin, supporting clinical supply, analytical testing, and process development alongside research sites in Pasadena and San Diego, California.
- Biopharmaceutical Strategic Collaborations: Multi-program research and licensing agreements with global pharmaceutical companies to co-develop and commercialize targeted RNA interference therapeutics across cardiometabolic, liver, pulmonary, and central nervous system disease indications.
Arrowhead Pharmaceuticals executive team
- Dr. Christopher R. Anzalone Ph.D.Chairman, CEO & President
- Mr. Daniel J. ApelChief Financial Officer
- Mr. Patrick O'Brien J.D., PharmDCOO & Secretary
- Dr. James C. Hamilton M.D., MBAChief Medical Officer and Head of R&D
- Dr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & Calando
- Dr. Vincent Anzalone CFAHead of Investor Relations & VP
- Mr. Howard LovyDirector of Communications
- Dr. Bruce D. Given M.D.Chief Medical Scientist
- Dr. Mark SeefeldHead of Toxicology & VP
- Aaron TanHead of Tax